Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1 Независимый исследователь в области психофармакологии, Израиль, Азур 5801726, ул. Бен-Гурион 26/7; 2 ФГБОУ «Ставропольский государственный медицинский университет», Российская Федерация, г. Ставрополь, 355017, ул. Мира, 310.
Список исп. литературыСкрыть список 1. Adedoyin A, Branch RA. Pharmacokinetics. In: Zakim D, Boyer TD, et al., editors. Hepatology: A Textbook of Liver Disease. 3 ed. Philadelphia: Saunders Elsevier; 1996. 2. Almasio P, Pagliaro L. [Ademetionine: the state of the art and future prospects]. [Article in Italian]. Ann Ital Med Int. 1993;8 Suppl:52S-55S. 3. Andrade RJ, Lucena MI, Alcantara R, Fraile JM. Bentazepam-associated chronic liver disease. Lancet. 1994;343:860. 4. Andrade RJ, Lucena MI, Fernández MC et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129:512–21. 5. Angulo P. Use of ursodeoxycholic acid in patients with liver disease. Curr Gastroenterol Rep. 2002;4(1):37-44. 6. Aronson JK. Meyler’s Side Effects of Psychiatric Drugs. Oxford: Elsevier; 2009. 7. Beers MH, Berkow R. The Merck Manual of Diagnosis and Therapy. 17 ed. West Point, PA: Merck and Co, Inc; 1999. 8. Biour M, Salem CB, Chazouillères O, Grangé J-D, Serfati L, Poupon R. Hépatotoxicité des médicaments 14e mise à jour du fichier bibliographique des atteintes hépatiques et des médicaments responsables. Gastroentérologie Clinique et Biologique. 2004;28:720–59. 9. Blusztajn JK, Slack BE, Mellott TJ. Neuroprotective actions of dietary choline. Nutrients . 2017;9(8). 10. Calandra C, Zappalà E, Bonomo V, Rapisarda V. 5-hydroxytryptophan in combination with allopurinol in depressions. Minerva Psichiatr. 1981;22(3):131-135. 11. Capuzzi E, Caldiroli A, Quitadamo C et al. Novel pharmacotherapy targeting the positive symptoms of schizophrenia. Expert Opin Pharmacother. 2023;1-26. doi: 10.1080/14656566.2023.2231346. 12. Carr CN, Straley CM, Baugh TB. Allopurinol for the Treatment of Refractory Aggression: A Case Series. Pharmacotherapy. 2017;37(6):748-754. doi: 10.1002/phar.1943. 13. Carrier P, Debette-Gratien M, Girard M et al. Liver Illness and Psychiatric Patients. Hepat Mon. 2016;16(12):e41564. 14. Chen B, Yang Y, Li S, Zhu X, Qi Y, Hong F. The critical role of hippocampal dopamine in the pathogenesis of hepatic encephalopathy. Physiol Res. 2021;70(1):101-110. doi: 10.33549/physiolres.934563. 15. Cho IJ, Oh DH, Yoo J et al. Allopurinol ameliorates high fructose diet induced hepatic steatosis in diabetic rats through modulation of lipid metabolism, inflammation, and ER stress pathway. Sci Rep. 2021;11(1):9894. doi: 10.1038/s41598-021-88872-7. 16. Coman HG, Herţa DC, Nemeş B. Psychiatric Adverse Effects Of Interferon Therapy. Clujul Med. 2013;86(4):318-20. 17. Cotter TG, Beresford T. Treatment of Mental Health in Patients With Chronic Liver Disease. Clin Liver Dis (Hoboken). 2022;20(2):57-60. 18. Crewe H, Lennard M, Tucker G, et al. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol. 1992;34:262–265. 19. Cutler JR, Pane O, Panesar SK et al. Treatment of Mood and Depressive Disorders With Complementary and Alternative Medicine: Efficacy Review. J Midwifery Womens Health. 2023;68(4):421-429. doi: 10.1111/jmwh. 13527. 20. DE Hert M, Schreurs V, Vancampfort D, VAN Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry. 2009;8:15–22. 21. Derby LE, Gutthann SP, Jick H, Dean AD. Liver disorders in patients receiving chlorpromazine or isoniazid. Pharmacotherapy. 1993;13:353–358. 22. Doweiko H. Concepts of Chemical Dependency. 8 ed. Belmont: Brooks/Cole; 2009. 23. Erdogan A, Kocabasoglu N, Yalug I, Ozbay G, Senturk H. Management of marked liver enzyme increase during clozapine treatment: a case report and review of the literature. Int J Psychiatry Med. 2004;34:83–89. 24. Farzaei MH, Zobeiri M, Parvizi F et al. Curcumin in Liver Diseases: A Systematic Review of the Cellular Mechanisms of Oxidative Stress and Clinical Perspective. Nutrients. 2018;10(7):855. 25. Gaertner I, Altendorf K, Batra A, Gaertner HJ. Relevance of liver enzyme elevations with four different neuroleptics: a retrospective review of 7,263 treatment courses. J Clin Psychopharmacol. 2001;21:215–222. 26. Gibbons RD, Hur K, Brown CH, et al. Benefits from antidepressants: synthesis of 6‐week patient‐level outcomes from double‐blind placebo‐controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry 2012;69:572‐579. 27. Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab. 2002;3:13–37. 28. Huang F. Ursodeoxycholic acid as a potential alternative therapeutic approach for neurodegenerative disorders: Effects on cell apoptosis, oxidative stress and inflammation in the brain. Brain Behav Immun Health. 2021;18:100348. 29. Huang Y, Wang X, Yan C et al. Effect of metformin on nonalcoholic fatty liver based on meta-analysis and network pharmacology. Medicine (Baltimore). 2022;101(43):e31437. 30. Ichinose M, Miura I, Horikoshi S et al. Memantine for Behavioral Symptoms of Hepatic Encephalopathy Associated With Alcoholic Cirrhosis: A Case Report. J Clin Psychopharmacol. 2021;41(1):85-86. doi: 10.1097/JCP.0000000000001326. 31. Izzo C, Annunziata M, Melara G et al. The Role of Resveratrol in Liver Disease: A Comprehensive Review from In Vitro to Clinical Trials. Nutrients. 2021;13(3):933. 32. Jacques J, Carrier P, Debette-Gratien M, Sobesky R, Loustaud-Ratti V. [Hepatic encephalopathy]. Presse Med. 2016;45(1):46–59. 33. Jahangard L, Soroush S, Haghighi M et al. In a double-blind, randomized and placebo-controlled trial, adjuvant allopurinol improved symptoms of mania in in-patients suffering from bipolar disorder. Eur Neuropsychopharmacol. 2014;24(8):1210-21. doi: 10.1016/j.euroneuro.2014.05.013. 34. Junker AE, Als-Nielsen B, Gluud C, Gluud LL. Dopamine agents for hepatic encephalopathy. Cochrane Database Syst Rev. 2014;(2):CD003047. doi: 10.1002/14651858.CD003047.pub3. 35. Kamps BS. Hepatology: a clinical textbook. Dusseldorf, Germany: Flying Publishing, 2010. 684 p. ISBN 978-3941727229. 36. Kim Y-H, Lee YJ, Jeong Y-Y, et al. The effect of metformin on liver lipid accumulation in mice fed a high-fat diet. J Korean Soc Appl Biol Chem. 2010;53:198–205. 37. Lai SW, Hwang BF, Kuo YH et al. Allopurinol use and the risk of dementia: A meta-analysis of case-control studies. Medicine (Baltimore). 2022;101 (26):e29827. doi: 10.1097/MD.0000000000029827. 38. Lamanna-Rama N, Romero-Miguel D, Desco M et al. An Update on the Exploratory Use of Curcumin in Neuropsychiatric Disorders. Antioxidants (Basel). 2022;11(2):353. 39. Li XY, Zhao ZX, Huang M et al. Effect of Berberine on promoting the excretion of cholesterol in high-fat diet-induced hyperlipidemic hamsters. Journal of Translational Medicine. 2015;13, article 278. 40. Li Y, Liu L, Wang B, et al. Metformin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Bio Rep. 2013;1:57–64. 41. Mandrioli R, Mercolini L, Raggi MA. Evaluation of the pharmacokinetics, safety and clinical efficacy of sertraline used to treat social anxiety. Expert Opin Drug Metab Toxicol. 2013;9:1495–1505. 42. Marwick KF, Taylor M, Walker SW. Antipsychotics and abnormal liver function tests: systematic review. Clin Neuropharmacol. 2012;35:244–253. 43. Masterton GS, Plevris JN, Hayes PC. Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2010;31:679–92. 44. Mehedint MG, Zeisel SH. Choline’s role in maintaining liver function: new evidence for epigenetic mechanisms. Curr Opin Clin Nutr Metab Care. 2013;16(3):339–345. 45. Menon V, Ransing R, Praharaj SK. Management of Psychiatric Disorders in Patients with Hepatic and Gastrointestinal Diseases. Indian J Psychiatry. 2022;64(Suppl 2):S379–S393. 46. Mullish BH, Kabir MS, Thursz MR, et al. Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation. Aliment Pharmacol Ther 2014;40:880‐892. 47. Patten SB. Psychiatric side effects of interferon treatment. Curr Drug Saf. 2006;1(2):143-50. 48. Peet M, Stokes C. Omega-3 fatty acids in the treatment of psychiatric disorders. Drugs. 2005;65(8):1051-9. 49. Pettinelli P, Del Pozo T, Araya J, et al. Enhancement in liver SREBP-1c/PPAR-alpha ratio and steatosis in obese patients: correlations with insulin resistance and n-3 long-chain polyunsaturated fatty acid depletion. Biochim Biophys Acta 2009;1792:1080–6. 50. Poly C, Massaro JM, Seshadri S et al. The relation of dietary choline to cognitive performance and white-matter hyperintensity in the Framingham Offspring Cohort1234. The American Journal of Clinical Nutrition. 2011;94(6):1584–1591. 51. Qaseem A, Barry MJ, Kansagara D. Clinical Guidelines Committee of the American College of Physicians. Nonpharmacologic versus pharmacologic treatment of adult patients with major depressive disorder: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2016;164:350‐359. 52. Rajpurohit S, Musunuri B, Shailesh S et al. Novel Drugs for the Management of Hepatic Encephalopathy: Still a Long Journey to Travel. J Clin Exp Hepatol. 2022;12(4):1200-1214. doi: 10.1016/j.jceh.2022.01.012. 53. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer‐term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905‐1917. 54. Sari DR, Soetoko AR, Soetoko AS et al. Uric acid induces liver fibrosis through activation of inflammatory mediators and proliferating hepatic stellate cell in mice. Med J Malaysia. 2020;75(Suppl 1):14-18. 55. Satapathy SK, Ochani M, Dancho M et al. Galantamine alleviates inflammation and other obesity-associated complications in high-fat diet-fed mice. Mol Med. 2011;17(7-8):599-606. doi: 10.2119/molmed.2011.00083. 56. Selim K, Kaplowitz N. Hepatotoxicity of psychotropic drugs. Hepatology. 1999;29:1347–1351. 57. Sharma A, Gerbarg P, Bottiglieri T et al. S-Adenosylmethionine (SAMe) for Neuropsychiatric Disorders: A Clinician-Oriented Review of Research. J Clin Psychiatry. 2017;78(6):e656-e667. doi: 10.4088/JCP.16r11113. 58. Shayganfard M. Berberine: Is it a Promising Agent for Mental Disorders Treatment? Curr Mol Pharmacol. 2023;16(3):307-320. 59. Shayganfard M. Molecular and biological functions of resveratrol in psychiatric disorders: a review of recent evidence. Cell Biosci. 2020;10(1):128. 60. Shi XY, Fan SM, Shi GM et al. Efficacy and safety of omega-3 fatty acids on liver-related outcomes in patients with nonalcoholic fatty liver disease. Medicine (Baltimore). 2020;99(24):e20624. 61. Stern SL, Mendels J. Drug combinations in the treatment of refractory depression: a review. J Clin Psychiatry. 1981;42(10):368-373. 62. Telles-Correia D, Barbosa A, Cortez-Pinto H et al. Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity. World J Gastrointest Pharmacol Ther. 2017;8(1):26–38.doi: 10.4292/wjgpt.v8.i1.26 63. Thyrum PT, Wong YW, Yeh C. Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment. Prog Neuropsychopharmacol Biol Psychiatry. 2000;24(4):521–33. 64. Trask PC, Esper P, Riba M et al. Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J Clin Oncol. 2000;18(11):2316-26. 65. Urichuk L, Prior TI, Dursun S, Baker G. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008;9:410–418. 66. Velazquez R, Ferreira E, Knowles S et al. Lifelong choline supplementation ameliorates Alzheimer’s disease pathology and associated cognitive deficits by attenuating microglia activation. Aging Cell . 2019;18(6). 67. Voican CS, Corruble E, Naveau S, Perlemuter G. Antidepressant-induced liver injury: a review for clinicians. Am J Psychiatry. 2014;171:404–415. 68. Vostrikov GP, Toporkov AS. [Use of heptral in chronic liver diseases]. [Article in Russian]. Eksp Klin Gastroenterol. 2002;(6):52-54,113. 69. Vukotić NT, Đorđević J, Pejić S et al. Antidepressants- and antipsychotics-induced hepatotoxicity. Arch Toxicol. 2021;95(3):767–789. 70. Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc. 2006;81(10):1361-7. 71. Wei X, Wang C, Hao S et al. The Therapeutic Effect of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis. Evid Based Complement Alternat Med. 2016; 2016: 3593951. 72. Withers N. The Liver-Impaired Patient. In: Leigh H, Streltzer J, editors. Handbook of Consultation Liason Psychiatry. New York: Springer; 2008. pp. 248–269. 73. Wu Chou AI, Lu ML, Shen WW. Hepatotoxicity induced by clozapine: A case report and review of literature. Neuropsychiatr Dis Treat. 2014;10:1585–1587. 74. Zakaria EM, Abdel-Ghany RH, Elgharbawy AS et al. A novel approach to repositioning memantine for metabolic syndrome-induced steatohepatitis: Modulation of hepatic autophagy, inflammation, and fibrosis. Life Sci. 2023;319:121509. doi: 10.1016/j.lfs.2023.121509. 75. Zhao Q, Iyer GR, Verhaeghe T, Truyen L. Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers. J Clin Pharmacol. 2002 Apr;42(4):428-36. 76. Zhou Y, Cao S, Wang Y et al. Berberine metabolites could induce low density lipoprotein receptor up-regulation to exert lipid-lowering effects in human hepatoma cells. Fitoterapia. 2014;92:230–237.